Charcot Marie Tooth Disease - Drug Pipeline Insights and Competitive Landscape, 2026 | 15+ Drugs Signal Gene Therapy and Neuromuscular Innovation Opportunities

Dublin, Oct. 22, 2026 -- "Charcot Marie Tooth Disease - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive analysis of the Charcot-Marie-Tooth disease pipeline, covering 13+ companies and 15+ investigational therapies across clinical and nonclinical development. It evaluates pipeline candidates by development phase, product type, molecule type and route of administration, while also examining discontinued and inactive programs.

Charcot-Marie-Tooth disease involves genetically driven peripheral nerve dysfunction affecting motor and sensory pathways. More than 100 genes have been implicated, including PMP22, MPZ and GJB1, contributing to substantial clinical and genetic heterogeneity across subtypes such as CMT1, CMT2 and CMTX. Disease manifestations commonly include progressive distal muscle weakness, sensory loss, muscle wasting, high arches, hammertoes, impaired balance, fatigue, pain and reduced fine motor function.

Diagnosis typically combines clinical evaluation, electrophysiological testing and genetic analysis. Nerve conduction studies and electromyography help distinguish demyelinating and axonal disease forms, while genetic testing can confirm specific pathogenic mutations. Current management remains primarily supportive and may include physical therapy, occupational therapy, orthotic devices, pain management and corrective surgery. Research programs are increasingly focused on disease-modifying strategies, including gene therapy, neuromuscular modulation and HDAC6 inhibition.

Charcot-Marie-Tooth Disease Pipeline Analysis

The report assesses the commercial and clinical potential of emerging Charcot-Marie-Tooth disease therapies. Individual drug profiles include mechanisms of action, clinical study information, regulatory status, development technologies, funding, designations and product-related activity. The analysis also reviews collaborations, licensing agreements, mergers and acquisitions involving companies and academic organizations active in Charcot-Marie-Tooth disease research and development.

Pipeline coverage includes candidates in Phase III, Phase II and Phase I trials, as well as pre-clinical and discovery-stage programs. The report examines clinical trial progress, pharmacological activity, development agreements and recent company announcements to identify trends that may influence the future Charcot-Marie-Tooth disease treatment landscape.

Selected Emerging Charcot-Marie-Tooth Disease Therapies

Ignaseclant: NMD PHARMA

Ignaseclant, also known as NMD670, is an investigational first-in-class oral small molecule designed to selectively inhibit the skeletal muscle chloride channel ClC-1. The candidate is intended to increase muscle excitability, improve neuromuscular signal transmission and support muscle function in patients with Charcot-Marie-Tooth disease. Ignaseclant is undergoing Phase II clinical evaluation and represents one of the most advanced pipeline programs included in the report.

EN001: ENCell

EN001 is an investigational therapy targeting pathways associated with muscle strength, nerve signaling and neuromuscular performance. The program aims to address functional impairment and fatigue associated with Charcot-Marie-Tooth disease. EN001 has completed Phase I clinical development.

Therapeutic Assessment

The Charcot-Marie-Tooth disease pipeline is segmented across multiple development and product categories:

• Development phases: Phase III, Phase II, Phase I, pre-clinical, discovery, discontinued and inactive programs
• Routes of administration: Oral, intravenous, subcutaneous, parenteral and topical
• Molecule types: Recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies
• Product types: Monotherapy, combination therapy and candidates with mono/combination development strategies

Charcot-Marie-Tooth Disease Market and Research Highlights

• Approximately 13+ companies are developing Charcot-Marie-Tooth disease therapies.
• The pipeline includes around 15+ products across clinical, pre-clinical and discovery stages.
• NMD PHARMA has a Phase II candidate among the most advanced programs assessed.
• Novel research approaches are targeting muscle excitability, neuromuscular signaling, genetic mechanisms and disease-specific molecular pathways.
• The report evaluates unmet needs, potential drug impact, pipeline progression and inactive candidates.
• Industry-Industry and Industry-Academia partnerships are assessed alongside licensing, funding, mergers and acquisitions.

Key Companies

• NMD PHARMA A/S
• ENCell
• Novartis
• Elpida Therapeutics
• Augustine Therapeutics
• Armatus Bio

Key Pipeline Products

• Ignaseclant
• EN001
• EDK060
• ELP-0
• AGT-100216
• TVR110

The report supports stakeholders seeking insight into the competitive Charcot-Marie-Tooth disease pipeline, including the number of therapies under development, their clinical status, emerging drug classes and the companies leading research. It also addresses recent clinical studies, regulatory designations, novel technologies and strategic partnerships that may shape future treatment options.

Key Topics Covered:

Introduction

Executive Summary

Charcot Marie Tooth disease: Overview

• Introduction
• Causes
• Pathophysiology
• Signs and Symptoms
• Diagnosis
• Treatment

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Charcot Marie Tooth disease- Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Ignaseclant: NMD PHARMA A/S

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Early Stage Products (Phase I)

• Comparative Analysis

EN001: ENCell

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

Inactive Products

• Comparative Analysis

Charcot Marie Tooth disease Key Companies

Charcot Marie Tooth disease Key Products

Charcot Marie Tooth disease- Unmet Needs

Charcot Marie Tooth disease- Market Drivers and Barriers

Charcot Marie Tooth disease- Future Perspectives and Conclusion

Charcot Marie Tooth disease Analyst Views

Appendix

List of Tables [12]

List of Figures [12]

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ywyyrb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.